Trial Outcomes & Findings for A Clinical Evidence Study Evaluating Quality of Life Parameters Following Treatment With Robitussin (NCT NCT06716645)
NCT ID: NCT06716645
Last Updated: 2026-02-20
Results Overview
The WURSS was an evaluative illness-specific quality of life instrument, designed to assess the negative impact of acute upper respiratory infection, presumed viral (the common cold). WURSS-21 was the short version of this validated survey. Participants rated their cold symptoms (10 questions) and Quality of Life (QoL) related 9 questions using WURSS-21. The responses were evaluated on a scale ranging from 0 to 7, where 0=Do not have symptoms/Not at all and 7=Severe symptoms/Severely. Thus, the minimum and maximum possible total scores were 0 and 133 respectively, where higher total scores indicated more negative impact on symptoms and quality of life. Change from Baseline was calculated as each post-Baseline value minus Baseline value. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).
COMPLETED
PHASE4
244 participants
Baseline and up to Day 7 or End of Treatment (EOT)
2026-02-20
Participant Flow
This study was conducted at a single center in United States of America.
A total of 244 participants were enrolled and randomized to two treatment groups: 122 to Group 1 (Daytime) and 122 to Group 2 (Daytime + Nighttime). A total of 110 participants from the Daytime group and 109 participants from the Daytime + Nighttime group completed the study.
Participant milestones
| Measure |
Robitussin Cough Syrup (Daytime)
Participants were instructed to take up to 20 milliliters (ml) of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
|---|---|---|
|
Overall Study
STARTED
|
122
|
122
|
|
Overall Study
COMPLETED
|
110
|
109
|
|
Overall Study
NOT COMPLETED
|
12
|
13
|
Reasons for withdrawal
| Measure |
Robitussin Cough Syrup (Daytime)
Participants were instructed to take up to 20 milliliters (ml) of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
|---|---|---|
|
Overall Study
Unable to deliver study product
|
4
|
7
|
|
Overall Study
Lost to Follow-up
|
6
|
2
|
|
Overall Study
Ineligibility
|
2
|
2
|
|
Overall Study
Non-compliance
|
0
|
2
|
Baseline Characteristics
A Clinical Evidence Study Evaluating Quality of Life Parameters Following Treatment With Robitussin
Baseline characteristics by cohort
| Measure |
Robitussin Cough Syrup (Daytime)
n=115 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=112 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
Total
n=227 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
40.7 years
STANDARD_DEVIATION 11.4 • n=14 Participants
|
39.4 years
STANDARD_DEVIATION 11.2 • n=14 Participants
|
40.1 years
STANDARD_DEVIATION 11.3 • n=29 Participants
|
|
Sex: Female, Male
Female
|
73 Participants
n=14 Participants
|
71 Participants
n=14 Participants
|
144 Participants
n=29 Participants
|
|
Sex: Female, Male
Male
|
42 Participants
n=14 Participants
|
41 Participants
n=14 Participants
|
83 Participants
n=29 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
13 Participants
n=14 Participants
|
12 Participants
n=14 Participants
|
25 Participants
n=29 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
102 Participants
n=14 Participants
|
99 Participants
n=14 Participants
|
201 Participants
n=29 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=14 Participants
|
1 Participants
n=14 Participants
|
1 Participants
n=29 Participants
|
|
Race/Ethnicity, Customized
Asian
|
8 Participants
n=14 Participants
|
5 Participants
n=14 Participants
|
13 Participants
n=29 Participants
|
|
Race/Ethnicity, Customized
Black or African American
|
23 Participants
n=14 Participants
|
28 Participants
n=14 Participants
|
51 Participants
n=29 Participants
|
|
Race/Ethnicity, Customized
Hispanic
|
1 Participants
n=14 Participants
|
2 Participants
n=14 Participants
|
3 Participants
n=29 Participants
|
|
Race/Ethnicity, Customized
Latino
|
1 Participants
n=14 Participants
|
0 Participants
n=14 Participants
|
1 Participants
n=29 Participants
|
|
Race/Ethnicity, Customized
Middle Eastern
|
0 Participants
n=14 Participants
|
1 Participants
n=14 Participants
|
1 Participants
n=29 Participants
|
|
Race/Ethnicity, Customized
Mixed
|
1 Participants
n=14 Participants
|
1 Participants
n=14 Participants
|
2 Participants
n=29 Participants
|
|
Race/Ethnicity, Customized
Multiple
|
6 Participants
n=14 Participants
|
7 Participants
n=14 Participants
|
13 Participants
n=29 Participants
|
|
Race/Ethnicity, Customized
Native Hawaiian / Other Pacific Islander
|
1 Participants
n=14 Participants
|
0 Participants
n=14 Participants
|
1 Participants
n=29 Participants
|
|
Race/Ethnicity, Customized
White
|
74 Participants
n=14 Participants
|
67 Participants
n=14 Participants
|
141 Participants
n=29 Participants
|
|
Race/Ethnicity, Customized
Missing
|
0 Participants
n=14 Participants
|
1 Participants
n=14 Participants
|
1 Participants
n=29 Participants
|
PRIMARY outcome
Timeframe: Baseline and up to Day 7 or End of Treatment (EOT)Population: The modified Intent-To-Treat (mITT) population included all participants who used study product at least once and had data from at least one post baseline QoL questionnaire to support at least one of the primary endpoint assessments. Only those participants with data available at the specified timepoint were analyzed.
The WURSS was an evaluative illness-specific quality of life instrument, designed to assess the negative impact of acute upper respiratory infection, presumed viral (the common cold). WURSS-21 was the short version of this validated survey. Participants rated their cold symptoms (10 questions) and Quality of Life (QoL) related 9 questions using WURSS-21. The responses were evaluated on a scale ranging from 0 to 7, where 0=Do not have symptoms/Not at all and 7=Severe symptoms/Severely. Thus, the minimum and maximum possible total scores were 0 and 133 respectively, where higher total scores indicated more negative impact on symptoms and quality of life. Change from Baseline was calculated as each post-Baseline value minus Baseline value. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).
Outcome measures
| Measure |
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
|---|---|---|
|
Adjusted Mean Change From Baseline in Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) Total Score
Day 1
|
-9.56 score on a scale
Interval -14.45 to -4.66
|
-9.11 score on a scale
Interval -13.49 to -4.73
|
|
Adjusted Mean Change From Baseline in Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) Total Score
Day 2
|
-26.49 score on a scale
Interval -31.51 to -21.47
|
-22.97 score on a scale
Interval -27.43 to -18.51
|
|
Adjusted Mean Change From Baseline in Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) Total Score
Day 3
|
-40.99 score on a scale
Interval -46.09 to -35.89
|
-36.71 score on a scale
Interval -41.28 to -32.14
|
|
Adjusted Mean Change From Baseline in Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) Total Score
Day 4
|
-47.63 score on a scale
Interval -53.07 to -42.18
|
-47.20 score on a scale
Interval -52.0 to -42.4
|
|
Adjusted Mean Change From Baseline in Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) Total Score
Day 5
|
-51.20 score on a scale
Interval -57.14 to -45.25
|
-55.05 score on a scale
Interval -60.13 to -49.96
|
|
Adjusted Mean Change From Baseline in Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) Total Score
Day 6
|
-58.29 score on a scale
Interval -64.83 to -51.75
|
-64.12 score on a scale
Interval -69.53 to -58.72
|
|
Adjusted Mean Change From Baseline in Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) Total Score
Day 7
|
-61.58 score on a scale
Interval -69.87 to -53.3
|
-64.69 score on a scale
Interval -72.62 to -56.76
|
|
Adjusted Mean Change From Baseline in Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) Total Score
EOT
|
-55.64 score on a scale
Interval -60.25 to -51.03
|
-53.62 score on a scale
Interval -57.7 to -49.55
|
PRIMARY outcome
Timeframe: Baseline and up to Day 7 or EOTPopulation: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).
The WURSS was an evaluative illness specific quality of life instrument, designed to assess the negative impact of acute upper respiratory infection, presumed viral (the common cold). WURSS-21 was the short version of this validated survey. The symptom domain of WURSS-21 consisted of 10 questions. Participants rated their cold symptoms related questions and the responses were evaluated on a scale ranging from 0 to 7, where 0=Do not have symptoms and 7=Severe. Thus, the minimum and maximum possible total score was 0 and 70 respectively, where higher scores indicated more negative impact on symptoms. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.
Outcome measures
| Measure |
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
|---|---|---|
|
Adjusted Mean Change From Baseline in WURSS-21 Total Symptom Domain Score
Day 1
|
-6.48 score on a scale
Interval -9.0 to -3.95
|
-5.89 score on a scale
Interval -8.27 to -3.51
|
|
Adjusted Mean Change From Baseline in WURSS-21 Total Symptom Domain Score
Day 2
|
-14.59 score on a scale
Interval -17.18 to -12.0
|
-13.58 score on a scale
Interval -15.99 to -11.16
|
|
Adjusted Mean Change From Baseline in WURSS-21 Total Symptom Domain Score
Day 3
|
-22.56 score on a scale
Interval -25.19 to -19.93
|
-21.26 score on a scale
Interval -23.73 to -18.79
|
|
Adjusted Mean Change From Baseline in WURSS-21 Total Symptom Domain Score
Day 4
|
-25.97 score on a scale
Interval -28.79 to -23.16
|
-26.58 score on a scale
Interval -29.16 to -24.0
|
|
Adjusted Mean Change From Baseline in WURSS-21 Total Symptom Domain Score
Day 5
|
-28.05 score on a scale
Interval -31.13 to -24.98
|
-30.46 score on a scale
Interval -33.19 to -27.74
|
|
Adjusted Mean Change From Baseline in WURSS-21 Total Symptom Domain Score
Day 6
|
-31.76 score on a scale
Interval -35.15 to -28.37
|
-35.40 score on a scale
Interval -38.28 to -32.52
|
|
Adjusted Mean Change From Baseline in WURSS-21 Total Symptom Domain Score
Day 7
|
-32.41 score on a scale
Interval -36.72 to -28.11
|
-37.07 score on a scale
Interval -41.21 to -32.93
|
|
Adjusted Mean Change From Baseline in WURSS-21 Total Symptom Domain Score
EOT
|
-30.03 score on a scale
Interval -32.4 to -27.66
|
-30.14 score on a scale
Interval -32.34 to -27.95
|
PRIMARY outcome
Timeframe: Baseline and up to Day 7 or EOTPopulation: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).
The WURSS was an evaluative illness specific quality of life instrument, designed to assess the negative impact of acute upper respiratory infection, presumed viral (the common cold). WURSS-21 was the short version of this validated survey. The QoL domain of WURSS-21 consisted of 9 questions. Participants rated their QoL related questions and the responses were evaluated on a scale ranging from 0 to 7, where 0=Not at all and 7=Severely. Thus, the minimum and maximum possible total scores were 0 and 63 respectively, where higher scores indicated more negative impact on QoL. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.
Outcome measures
| Measure |
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
|---|---|---|
|
Adjusted Mean Change From Baseline in WURSS-21 Total QoL Domain Score
Day 1
|
-3.06 score on a scale
Interval -5.71 to -0.4
|
-3.28 score on a scale
Interval -5.73 to -0.83
|
|
Adjusted Mean Change From Baseline in WURSS-21 Total QoL Domain Score
Day 2
|
-11.87 score on a scale
Interval -14.59 to -9.16
|
-9.44 score on a scale
Interval -11.94 to -6.93
|
|
Adjusted Mean Change From Baseline in WURSS-21 Total QoL Domain Score
Day 3
|
-18.40 score on a scale
Interval -21.16 to -15.63
|
-15.49 score on a scale
Interval -18.07 to -12.91
|
|
Adjusted Mean Change From Baseline in WURSS-21 Total QoL Domain Score
Day 4
|
-21.56 score on a scale
Interval -24.52 to -18.6
|
-20.61 score on a scale
Interval -23.34 to -17.87
|
|
Adjusted Mean Change From Baseline in WURSS-21 Total QoL Domain Score
Day 5
|
-23.05 score on a scale
Interval -26.29 to -19.81
|
-24.54 score on a scale
Interval -27.46 to -21.62
|
|
Adjusted Mean Change From Baseline in WURSS-21 Total QoL Domain Score
Day 6
|
-26.40 score on a scale
Interval -29.98 to -22.83
|
-28.63 score on a scale
Interval -31.76 to -25.5
|
|
Adjusted Mean Change From Baseline in WURSS-21 Total QoL Domain Score
Day 7
|
-28.99 score on a scale
Interval -33.54 to -24.44
|
-27.55 score on a scale
Interval -32.31 to -22.8
|
|
Adjusted Mean Change From Baseline in WURSS-21 Total QoL Domain Score
EOT
|
-25.57 score on a scale
Interval -28.08 to -23.05
|
-23.54 score on a scale
Interval -25.86 to -21.23
|
PRIMARY outcome
Timeframe: Baseline and up to Day 7 or EOTPopulation: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).
The WURSS was an evaluative illness specific quality of life instrument, designed to assess the negative impact of acute upper respiratory infection, presumed viral (the common cold). WURSS-21 was the short version of this validated survey. The individual symptoms included runny nose, plugged nose, sneezing, sore throat, scratchy throat, cough, hoarseness, head congestion, chest congestion and feeling tired. Participants rated each of the 10 individual symptom domain questions and the responses were evaluated on a scale ranging from 0 to 7, where 0=Do not have symptom and 7=Severe. Thus, the minimum and maximum score for each symptom domain question was 0 and 7, where higher scores indicated more negative impact on symptoms. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.
Outcome measures
| Measure |
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
|---|---|---|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Cough
Day 1
|
-0.87 score on a scale
Interval -1.2 to -0.54
|
-0.96 score on a scale
Interval -1.25 to -0.68
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Cough
Day 2
|
-1.91 score on a scale
Interval -2.26 to -1.57
|
-1.77 score on a scale
Interval -2.06 to -1.48
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Cough
Day 3
|
-2.91 score on a scale
Interval -3.26 to -2.57
|
-2.78 score on a scale
Interval -3.08 to -2.48
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Cough
Day 4
|
-3.34 score on a scale
Interval -3.71 to -2.96
|
-3.46 score on a scale
Interval -3.78 to -3.14
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Cough
Day 5
|
-3.66 score on a scale
Interval -4.07 to -3.25
|
-3.78 score on a scale
Interval -4.12 to -3.43
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Cough
Day 6
|
-4.01 score on a scale
Interval -4.47 to -3.55
|
-4.44 score on a scale
Interval -4.8 to -4.07
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Cough
Day 7
|
-4.29 score on a scale
Interval -4.88 to -3.7
|
-4.54 score on a scale
Interval -5.1 to -3.97
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Cough
EOT
|
-3.96 score on a scale
Interval -4.26 to -3.66
|
-3.92 score on a scale
Interval -4.19 to -3.65
|
PRIMARY outcome
Timeframe: Baseline and up to Day 7 or EOTPopulation: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).
The WURSS was an evaluative illness specific quality of life instrument, designed to assess the negative impact of acute upper respiratory infection, presumed viral (the common cold). WURSS-21 was the short version of this validated survey. The individual symptoms included runny nose, plugged nose, sneezing, sore throat, scratchy throat, cough, hoarseness, head congestion, chest congestion and feeling tired. Participants rated each of the 10 individual symptom domain questions and the responses were evaluated on a scale ranging from 0 to 7, where 0=Do not have symptom and 7=Severe. Thus, the minimum and maximum score for each symptom domain question was 0 and 7, where higher scores indicated more negative impact on symptoms. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.
Outcome measures
| Measure |
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
|---|---|---|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Runny Nose
Day 1
|
-0.65 score on a scale
Standard Deviation 1.49
|
-0.33 score on a scale
Standard Deviation 1.51
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Runny Nose
Day 2
|
-1.29 score on a scale
Standard Deviation 1.85
|
-1.02 score on a scale
Standard Deviation 1.70
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Runny Nose
Day 3
|
-2.05 score on a scale
Standard Deviation 1.93
|
-1.61 score on a scale
Standard Deviation 1.69
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Runny Nose
Day 4
|
-2.33 score on a scale
Standard Deviation 1.89
|
-1.97 score on a scale
Standard Deviation 2.11
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Runny Nose
Day 5
|
-2.23 score on a scale
Standard Deviation 2.05
|
-2.29 score on a scale
Standard Deviation 1.67
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Runny Nose
Day 6
|
-2.33 score on a scale
Standard Deviation 1.88
|
-2.71 score on a scale
Standard Deviation 1.84
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Runny Nose
Day 7
|
-2.48 score on a scale
Standard Deviation 1.63
|
-2.47 score on a scale
Standard Deviation 2.50
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Runny Nose
EOT
|
-2.80 score on a scale
Standard Deviation 1.93
|
-2.60 score on a scale
Standard Deviation 1.89
|
PRIMARY outcome
Timeframe: Baseline and up to Day 7 or EOTPopulation: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).
The WURSS was an evaluative illness specific quality of life instrument, designed to assess the negative impact of acute upper respiratory infection, presumed viral (the common cold). WURSS-21 was the short version of this validated survey. The individual symptoms included runny nose, plugged nose, sneezing, sore throat, scratchy throat, cough, hoarseness, head congestion, chest congestion and feeling tired. Participants rated each of the 10 individual symptom domain questions and the responses were evaluated on a scale ranging from 0 to 7, where 0=Do not have symptom and 7=Severe. Thus, the minimum and maximum score for each symptom domain question was 0 and 7, where higher scores indicated more negative impact on symptoms. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.
Outcome measures
| Measure |
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
|---|---|---|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Plugged Nose
Day 1
|
-0.58 score on a scale
Standard Deviation 1.63
|
-0.22 score on a scale
Standard Deviation 1.37
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Plugged Nose
Day 2
|
-1.25 score on a scale
Standard Deviation 1.88
|
-1.01 score on a scale
Standard Deviation 1.79
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Plugged Nose
Day 3
|
-1.94 score on a scale
Standard Deviation 2.08
|
-1.65 score on a scale
Standard Deviation 1.95
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Plugged Nose
Day 4
|
-2.09 score on a scale
Standard Deviation 2.03
|
-1.84 score on a scale
Standard Deviation 2.10
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Plugged Nose
Day 5
|
-2.15 score on a scale
Standard Deviation 2.13
|
-2.02 score on a scale
Standard Deviation 2.04
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Plugged Nose
Day 6
|
-2.15 score on a scale
Standard Deviation 2.12
|
-2.82 score on a scale
Standard Deviation 1.64
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Plugged Nose
Day 7
|
-2.14 score on a scale
Standard Deviation 2.13
|
-2.67 score on a scale
Standard Deviation 2.16
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Plugged Nose
EOT
|
-2.52 score on a scale
Standard Deviation 2.28
|
-2.52 score on a scale
Standard Deviation 1.93
|
PRIMARY outcome
Timeframe: Baseline and up to Day 7 or EOTPopulation: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).
The WURSS was an evaluative illness specific quality of life instrument, designed to assess the negative impact of acute upper respiratory infection, presumed viral (the common cold). WURSS-21 was the short version of this validated survey. The individual symptoms included runny nose, plugged nose, sneezing, sore throat, scratchy throat, cough, hoarseness, head congestion, chest congestion and feeling tired. Participants rated each of the 10 individual symptom domain questions and the responses were evaluated on a scale ranging from 0 to 7, where 0=Do not have symptom and 7=Severe. Thus, the minimum and maximum score for each symptom domain question was 0 and 7, where higher scores indicated more negative impact on symptoms. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.
Outcome measures
| Measure |
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
|---|---|---|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Sneezing
Day 1
|
-0.65 score on a scale
Standard Deviation 1.61
|
-0.59 score on a scale
Standard Deviation 1.53
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Sneezing
Day 2
|
-1.43 score on a scale
Standard Deviation 1.92
|
-1.09 score on a scale
Standard Deviation 1.77
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Sneezing
Day 3
|
-1.88 score on a scale
Standard Deviation 2.03
|
-1.60 score on a scale
Standard Deviation 1.80
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Sneezing
Day 4
|
-2.10 score on a scale
Standard Deviation 2.18
|
-1.83 score on a scale
Standard Deviation 1.80
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Sneezing
Day 5
|
-2.06 score on a scale
Standard Deviation 2.10
|
-1.75 score on a scale
Standard Deviation 1.64
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Sneezing
Day 6
|
-2.05 score on a scale
Standard Deviation 1.78
|
-2.04 score on a scale
Standard Deviation 1.51
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Sneezing
Day 7
|
-1.86 score on a scale
Standard Deviation 1.65
|
-2.00 score on a scale
Standard Deviation 1.96
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Sneezing
EOT
|
-2.64 score on a scale
Standard Deviation 1.93
|
-2.24 score on a scale
Standard Deviation 1.95
|
PRIMARY outcome
Timeframe: Baseline and up to Day 7 or EOTPopulation: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).
The WURSS was an evaluative illness specific quality of life instrument, designed to assess the negative impact of acute upper respiratory infection, presumed viral (the common cold). WURSS-21 was the short version of this validated survey. The individual symptoms included runny nose, plugged nose, sneezing, sore throat, scratchy throat, cough, hoarseness, head congestion, chest congestion and feeling tired. Participants rated each of the 10 individual symptom domain questions and the responses were evaluated on a scale ranging from 0 to 7, where 0=Do not have symptom and 7=Severe. Thus, the minimum and maximum score for each symptom domain question was 0 and 7, where higher scores indicated more negative impact on symptoms. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.
Outcome measures
| Measure |
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
|---|---|---|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Sore Throat
Day 1
|
-0.84 score on a scale
Standard Deviation 1.68
|
-0.70 score on a scale
Standard Deviation 1.57
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Sore Throat
Day 2
|
-1.65 score on a scale
Standard Deviation 1.91
|
-1.53 score on a scale
Standard Deviation 1.61
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Sore Throat
Day 3
|
-2.23 score on a scale
Standard Deviation 2.08
|
-2.26 score on a scale
Standard Deviation 1.78
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Sore Throat
Day 4
|
-2.36 score on a scale
Standard Deviation 2.04
|
-2.86 score on a scale
Standard Deviation 1.87
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Sore Throat
Day 5
|
-2.42 score on a scale
Standard Deviation 2.13
|
-2.70 score on a scale
Standard Deviation 1.76
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Sore Throat
Day 6
|
-2.72 score on a scale
Standard Deviation 1.92
|
-3.56 score on a scale
Standard Deviation 1.63
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Sore Throat
Day 7
|
-2.48 score on a scale
Standard Deviation 1.99
|
-3.27 score on a scale
Standard Deviation 1.67
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Sore Throat
EOT
|
-2.96 score on a scale
Standard Deviation 1.98
|
-3.23 score on a scale
Standard Deviation 1.87
|
PRIMARY outcome
Timeframe: Baseline and up to Day 7 or EOTPopulation: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).
The WURSS was an evaluative illness specific quality of life instrument, designed to assess the negative impact of acute upper respiratory infection, presumed viral (the common cold). WURSS-21 was the short version of this validated survey. The individual symptoms included runny nose, plugged nose, sneezing, sore throat, scratchy throat, cough, hoarseness, head congestion, chest congestion and feeling tired. Participants rated each of the 10 individual symptom domain questions and the responses were evaluated on a scale ranging from 0 to 7, where 0=Do not have symptom and 7=Severe. Thus, the minimum and maximum score for each symptom domain question was 0 and 7, where higher scores indicated more negative impact on symptoms. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.
Outcome measures
| Measure |
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
|---|---|---|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Scratchy Throat
Day 1
|
-0.72 score on a scale
Standard Deviation 1.64
|
-1.10 score on a scale
Standard Deviation 1.44
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Scratchy Throat
Day 2
|
-1.49 score on a scale
Standard Deviation 1.99
|
-1.91 score on a scale
Standard Deviation 1.87
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Scratchy Throat
Day 3
|
-2.28 score on a scale
Standard Deviation 2.27
|
-2.61 score on a scale
Standard Deviation 1.79
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Scratchy Throat
Day 4
|
-2.42 score on a scale
Standard Deviation 2.23
|
-3.11 score on a scale
Standard Deviation 1.69
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Scratchy Throat
Day 5
|
-2.62 score on a scale
Standard Deviation 2.20
|
-3.04 score on a scale
Standard Deviation 1.77
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Scratchy Throat
Day 6
|
-2.85 score on a scale
Standard Deviation 2.01
|
-3.73 score on a scale
Standard Deviation 1.54
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Scratchy Throat
Day 7
|
-3.05 score on a scale
Standard Deviation 2.09
|
-3.80 score on a scale
Standard Deviation 1.66
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Scratchy Throat
EOT
|
-3.06 score on a scale
Standard Deviation 1.99
|
-3.58 score on a scale
Standard Deviation 1.82
|
PRIMARY outcome
Timeframe: Baseline and up to Day 7 or EOTPopulation: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).
The WURSS was an evaluative illness specific quality of life instrument, designed to assess the negative impact of acute upper respiratory infection, presumed viral (the common cold). WURSS-21 was the short version of this validated survey. The individual symptoms include runny nose, plugged nose, sneezing, sore throat, scratchy throat, cough, hoarseness, head congestion, chest congestion and feeling tired. Participants rated each of the 10 individual symptom domain questions and the responses were evaluated on a scale ranging from 0 to 7, where 0=Do not have symptom and 7=Severe. Thus, the minimum and maximum score for each symptom domain question was 0 and 7, where higher scores indicated more negative impact on symptoms. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.
Outcome measures
| Measure |
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
|---|---|---|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Hoarseness
Day 1
|
-0.73 score on a scale
Standard Deviation 1.48
|
-0.54 score on a scale
Standard Deviation 1.58
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Hoarseness
Day 2
|
-1.66 score on a scale
Standard Deviation 1.78
|
-1.03 score on a scale
Standard Deviation 1.59
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Hoarseness
Day 3
|
-2.28 score on a scale
Standard Deviation 2.06
|
-1.91 score on a scale
Standard Deviation 1.59
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Hoarseness
Day 4
|
-2.38 score on a scale
Standard Deviation 2.11
|
-2.41 score on a scale
Standard Deviation 1.86
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Hoarseness
Day 5
|
-2.67 score on a scale
Standard Deviation 2.10
|
-2.62 score on a scale
Standard Deviation 2.06
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Hoarseness
Day 6
|
-2.72 score on a scale
Standard Deviation 2.08
|
-3.22 score on a scale
Standard Deviation 1.96
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Hoarseness
Day 7
|
-2.67 score on a scale
Standard Deviation 1.80
|
-3.07 score on a scale
Standard Deviation 2.09
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Hoarseness
EOT
|
-3.15 score on a scale
Standard Deviation 2.00
|
-2.95 score on a scale
Standard Deviation 2.06
|
PRIMARY outcome
Timeframe: Baseline and up to Day 7 or EOTPopulation: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).
The WURSS was an evaluative illness specific quality of life instrument, designed to assess the negative impact of acute upper respiratory infection, presumed viral (the common cold). WURSS-21 was the short version of this validated survey. The individual symptoms included runny nose, plugged nose, sneezing, sore throat, scratchy throat, cough, hoarseness, head congestion, chest congestion and feeling tired. Participants rated each of the 10 individual symptom domain questions and the responses were evaluated on a scale ranging from 0 to 7, where 0=Do not have symptom and 7=Severe. Thus, the minimum and maximum score for each symptom domain question was 0 and 7, where higher scores indicated more negative impact on symptoms. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.
Outcome measures
| Measure |
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
|---|---|---|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Head Congestion
Day 1
|
-0.54 score on a scale
Standard Deviation 1.68
|
-0.41 score on a scale
Standard Deviation 1.78
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Head Congestion
Day 2
|
-1.31 score on a scale
Standard Deviation 1.98
|
-0.92 score on a scale
Standard Deviation 1.77
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Head Congestion
Day 3
|
-1.95 score on a scale
Standard Deviation 2.31
|
-1.81 score on a scale
Standard Deviation 1.71
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Head Congestion
Day 4
|
-2.17 score on a scale
Standard Deviation 2.37
|
-1.94 score on a scale
Standard Deviation 2.29
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Head Congestion
Day 5
|
-2.21 score on a scale
Standard Deviation 2.25
|
-2.32 score on a scale
Standard Deviation 2.07
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Head Congestion
Day 6
|
-2.51 score on a scale
Standard Deviation 1.99
|
-3.00 score on a scale
Standard Deviation 1.75
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Head Congestion
Day 7
|
-2.38 score on a scale
Standard Deviation 2.42
|
-3.00 score on a scale
Standard Deviation 2.45
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Head Congestion
EOT
|
-2.91 score on a scale
Standard Deviation 2.06
|
-2.67 score on a scale
Standard Deviation 2.09
|
PRIMARY outcome
Timeframe: Baseline and up to Day 7 or EOTPopulation: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).
The WURSS was an evaluative illness specific quality of life instrument, designed to assess the negative impact of acute upper respiratory infection, presumed viral (the common cold). WURSS-21 was the short version of this validated survey. The individual symptoms included runny nose, plugged nose, sneezing, sore throat, scratchy throat, cough, hoarseness, head congestion, chest congestion and feeling tired. Participants rated each of the 10 individual symptom domain questions and the responses were evaluated on a scale ranging from 0 to 7, where 0=Do not have symptom and 7=Severe. Thus, the minimum and maximum score for each symptom domain question was 0 and 7, where higher scores indicated more negative impact on symptoms. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.
Outcome measures
| Measure |
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
|---|---|---|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Chest Congestion
Day 1
|
-0.55 score on a scale
Standard Deviation 1.57
|
-0.49 score on a scale
Standard Deviation 1.66
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Chest Congestion
Day 2
|
-1.30 score on a scale
Standard Deviation 1.88
|
-1.01 score on a scale
Standard Deviation 1.65
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Chest Congestion
Day 3
|
-1.95 score on a scale
Standard Deviation 1.78
|
-1.98 score on a scale
Standard Deviation 1.87
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Chest Congestion
Day 4
|
-2.13 score on a scale
Standard Deviation 1.76
|
-2.16 score on a scale
Standard Deviation 2.00
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Chest Congestion
Day 5
|
-2.33 score on a scale
Standard Deviation 2.02
|
-2.34 score on a scale
Standard Deviation 1.71
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Chest Congestion
Day 6
|
-2.31 score on a scale
Standard Deviation 1.76
|
-2.87 score on a scale
Standard Deviation 1.44
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Chest Congestion
Day 7
|
-2.33 score on a scale
Standard Deviation 1.65
|
-3.07 score on a scale
Standard Deviation 2.19
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Chest Congestion
EOT
|
-2.75 score on a scale
Standard Deviation 1.94
|
-2.82 score on a scale
Standard Deviation 1.92
|
PRIMARY outcome
Timeframe: Baseline and up to Day 7 or EOTPopulation: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).
The WURSS was an evaluative illness specific quality of life instrument, designed to assess the negative impact of acute upper respiratory infection, presumed viral (the common cold). WURSS-21 was the short version of this validated survey. The individual symptoms included runny nose, plugged nose, sneezing, sore throat, scratchy throat, cough, hoarseness, head congestion, chest congestion and feeling tired. Participants rated each of the 10 individual symptom domain questions and the responses were evaluated on a scale ranging from 0 to 7, where 0=Do not have symptom and 7=Severe. Thus, the minimum and maximum score for each symptom domain question was 0 and 7, where higher scores indicated more negative impact on symptoms. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.
Outcome measures
| Measure |
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
|---|---|---|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Feeling Tired
Day 1
|
-0.63 score on a scale
Standard Deviation 1.65
|
-0.68 score on a scale
Standard Deviation 1.52
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Feeling Tired
Day 2
|
-1.65 score on a scale
Standard Deviation 2.04
|
-1.42 score on a scale
Standard Deviation 1.64
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Feeling Tired
Day 3
|
-2.69 score on a scale
Standard Deviation 1.95
|
-2.20 score on a scale
Standard Deviation 1.93
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Feeling Tired
Day 4
|
-2.93 score on a scale
Standard Deviation 2.26
|
-2.61 score on a scale
Standard Deviation 1.96
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Feeling Tired
Day 5
|
-2.87 score on a scale
Standard Deviation 2.00
|
-2.95 score on a scale
Standard Deviation 1.80
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Feeling Tired
Day 6
|
-3.49 score on a scale
Standard Deviation 1.96
|
-3.51 score on a scale
Standard Deviation 1.74
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Feeling Tired
Day 7
|
-2.81 score on a scale
Standard Deviation 1.94
|
-3.47 score on a scale
Standard Deviation 2.03
|
|
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Feeling Tired
EOT
|
-3.47 score on a scale
Standard Deviation 2.02
|
-3.50 score on a scale
Standard Deviation 1.78
|
PRIMARY outcome
Timeframe: Baseline and up to Day 7 or EOTPopulation: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).
The WURSS was an evaluative illness specific quality of life instrument, designed to assess the negative impact of acute upper respiratory infection, presumed viral (the common cold). WURSS-21 was the short version of this validated survey. The QoL domain of WURSS-21 consisted of 9 questions. Participants rated each QoL questions indicating how cold interfered with their ability to perform daily activities, and the responses were evaluated on a scale ranging from 0 to 7, where 0=Not at all and 7=Severely. Thus, the minimum and maximum possible total scores were 0 and 7 respectively, where higher scores indicated more negative impact on QoL. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.
Outcome measures
| Measure |
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
|---|---|---|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Think Clearly
Day 1
|
-0.29 score on a scale
Standard Deviation 1.76
|
-0.34 score on a scale
Standard Deviation 1.67
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Think Clearly
Day 2
|
-1.11 score on a scale
Standard Deviation 2.02
|
-0.97 score on a scale
Standard Deviation 1.96
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Think Clearly
Day 3
|
-1.78 score on a scale
Standard Deviation 1.86
|
-1.55 score on a scale
Standard Deviation 2.22
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Think Clearly
Day 4
|
-1.81 score on a scale
Standard Deviation 2.43
|
-1.97 score on a scale
Standard Deviation 2.26
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Think Clearly
Day 5
|
-1.90 score on a scale
Standard Deviation 2.31
|
-1.88 score on a scale
Standard Deviation 2.27
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Think Clearly
Day 6
|
-2.41 score on a scale
Standard Deviation 2.04
|
-2.62 score on a scale
Standard Deviation 2.05
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Think Clearly
Day 7
|
-2.24 score on a scale
Standard Deviation 1.87
|
-2.13 score on a scale
Standard Deviation 3.50
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Think Clearly
EOT
|
-2.62 score on a scale
Standard Deviation 1.91
|
-2.41 score on a scale
Standard Deviation 2.35
|
PRIMARY outcome
Timeframe: Baseline and up to Day 7 or EOTPopulation: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).
The WURSS was an evaluative illness specific quality of life instrument, designed to assess the negative impact of acute upper respiratory infection, presumed viral (the common cold). WURSS-21 was the short version of this validated survey. The QoL domain of WURSS-21 consisted of 9 questions. Participants rated each QoL questions indicating how cold interfered with their ability to perform daily activities, and the responses were evaluated on a scale ranging from 0 to 7, where 0=Not at all and 7=Severely. Thus, the minimum and maximum possible total scores were 0 and 7 respectively, where higher scores indicate more negative impact on QoL. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.
Outcome measures
| Measure |
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
|---|---|---|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Sleep Well
Day 1
|
-0.92 score on a scale
Standard Deviation 2.22
|
-0.83 score on a scale
Standard Deviation 2.35
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Sleep Well
Day 2
|
-1.91 score on a scale
Standard Deviation 2.37
|
-1.57 score on a scale
Standard Deviation 2.40
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Sleep Well
Day 3
|
-2.58 score on a scale
Standard Deviation 2.40
|
-2.35 score on a scale
Standard Deviation 2.50
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Sleep Well
Day 4
|
-2.74 score on a scale
Standard Deviation 2.85
|
-2.66 score on a scale
Standard Deviation 2.39
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Sleep Well
Day 5
|
-2.83 score on a scale
Standard Deviation 2.66
|
-3.09 score on a scale
Standard Deviation 2.10
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Sleep Well
Day 6
|
-3.10 score on a scale
Standard Deviation 2.82
|
-3.47 score on a scale
Standard Deviation 2.31
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Sleep Well
Day 7
|
-2.24 score on a scale
Standard Deviation 2.51
|
-3.87 score on a scale
Standard Deviation 2.36
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Sleep Well
EOT
|
-3.63 score on a scale
Standard Deviation 2.34
|
-3.27 score on a scale
Standard Deviation 2.54
|
PRIMARY outcome
Timeframe: Baseline and up to Day 7 or EOTPopulation: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).
The WURSS was an evaluative illness specific quality of life instrument, designed to assess the negative impact of acute upper respiratory infection, presumed viral (the common cold). WURSS-21 was the short version of this validated survey. The QoL domain of WURSS-21 consisted of 9 questions. Participants rated each QoL questions indicating how cold interfered with their ability to perform daily activities, and the responses were evaluated on a scale ranging from 0 to 7, where 0=Not at all and 7=Severely. Thus, the minimum and maximum possible total scores were 0 and 7 respectively, where higher scores indicated more negative impact on QoL. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.
Outcome measures
| Measure |
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
|---|---|---|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Breathe Easily
Day 1
|
-0.47 score on a scale
Standard Deviation 1.80
|
-0.48 score on a scale
Standard Deviation 1.67
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Breathe Easily
Day 2
|
-1.40 score on a scale
Standard Deviation 2.02
|
-0.92 score on a scale
Standard Deviation 1.88
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Breathe Easily
Day 3
|
-2.27 score on a scale
Standard Deviation 1.88
|
-1.66 score on a scale
Standard Deviation 1.81
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Breathe Easily
Day 4
|
-2.48 score on a scale
Standard Deviation 2.36
|
-2.04 score on a scale
Standard Deviation 1.99
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Breathe Easily
Day 5
|
-2.38 score on a scale
Standard Deviation 2.09
|
-2.21 score on a scale
Standard Deviation 1.98
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Breathe Easily
Day 6
|
-2.41 score on a scale
Standard Deviation 2.02
|
-2.87 score on a scale
Standard Deviation 1.85
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Breathe Easily
Day 7
|
-1.86 score on a scale
Standard Deviation 2.03
|
-2.00 score on a scale
Standard Deviation 1.89
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Breathe Easily
EOT
|
-2.90 score on a scale
Standard Deviation 2.06
|
-2.52 score on a scale
Standard Deviation 2.11
|
PRIMARY outcome
Timeframe: Baseline and up to Day 7 or EOTPopulation: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).
The WURSS was an evaluative illness specific quality of life instrument, designed to assess the negative impact of acute upper respiratory infection, presumed viral (the common cold). WURSS-21 was the short version of this validated survey. The QoL domain of WURSS-21 consisted of 9 questions. Participants rated each QoL questions indicating how cold interfered with their ability to perform daily activities, and the responses were evaluated on a scale ranging from 0 to 7, where 0=Not at all and 7=Severely. Thus, the minimum and maximum possible total scores were 0 and 7 respectively, where higher scores indicated more negative impact on QoL. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.
Outcome measures
| Measure |
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
|---|---|---|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Walk, Climb Stairs, Exercise
Day 1
|
-0.43 score on a scale
Standard Deviation 1.80
|
-0.14 score on a scale
Standard Deviation 1.93
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Walk, Climb Stairs, Exercise
Day 2
|
-1.23 score on a scale
Standard Deviation 1.93
|
-0.66 score on a scale
Standard Deviation 2.15
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Walk, Climb Stairs, Exercise
Day 3
|
-1.70 score on a scale
Standard Deviation 1.96
|
-1.29 score on a scale
Standard Deviation 2.11
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Walk, Climb Stairs, Exercise
Day 4
|
-2.00 score on a scale
Standard Deviation 2.37
|
-1.76 score on a scale
Standard Deviation 2.13
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Walk, Climb Stairs, Exercise
Day 5
|
-1.87 score on a scale
Standard Deviation 2.13
|
-2.09 score on a scale
Standard Deviation 2.04
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Walk, Climb Stairs, Exercise
Day 6
|
-1.95 score on a scale
Standard Deviation 1.50
|
-2.60 score on a scale
Standard Deviation 1.84
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Walk, Climb Stairs, Exercise
Day 7
|
-2.10 score on a scale
Standard Deviation 1.61
|
-2.40 score on a scale
Standard Deviation 2.03
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Walk, Climb Stairs, Exercise
EOT
|
-2.55 score on a scale
Standard Deviation 2.03
|
-2.14 score on a scale
Standard Deviation 2.25
|
PRIMARY outcome
Timeframe: Baseline and up to Day 7 or EOTPopulation: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).
The WURSS was an evaluative illness specific quality of life instrument, designed to assess the negative impact of acute upper respiratory infection, presumed viral (the common cold). WURSS-21 was the short version of this validated survey. The QoL domain of WURSS-21 consisted of 9 questions. Participants rated each QoL questions indicating how cold interfered with their ability to perform daily activities, and the responses were evaluated on a scale ranging from 0 to 7, where 0=Not at all and 7=Severely. Thus, the minimum and maximum possible total scores were 0 and 7 respectively, where higher scores indicated more negative impact on QoL. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.
Outcome measures
| Measure |
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
|---|---|---|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Accomplish Daily Activities
Day 1
|
-0.44 score on a scale
Standard Deviation 1.81
|
-0.23 score on a scale
Standard Deviation 1.52
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Accomplish Daily Activities
Day 2
|
-1.46 score on a scale
Standard Deviation 1.83
|
-0.87 score on a scale
Standard Deviation 1.86
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Accomplish Daily Activities
Day 3
|
-2.17 score on a scale
Standard Deviation 1.96
|
-1.46 score on a scale
Standard Deviation 1.85
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Accomplish Daily Activities
Day 4
|
-2.28 score on a scale
Standard Deviation 2.27
|
-1.84 score on a scale
Standard Deviation 1.84
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Accomplish Daily Activities
Day 5
|
-2.13 score on a scale
Standard Deviation 1.85
|
-2.12 score on a scale
Standard Deviation 1.83
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Accomplish Daily Activities
Day 6
|
-2.38 score on a scale
Standard Deviation 1.63
|
-2.78 score on a scale
Standard Deviation 1.64
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Accomplish Daily Activities
Day 7
|
-2.43 score on a scale
Standard Deviation 1.69
|
-2.80 score on a scale
Standard Deviation 1.52
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Accomplish Daily Activities
EOT
|
-2.94 score on a scale
Standard Deviation 2.00
|
-2.56 score on a scale
Standard Deviation 1.93
|
PRIMARY outcome
Timeframe: Baseline and up to Day 7 or EOTPopulation: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).
The WURSS was an evaluative illness specific quality of life instrument, designed to assess the negative impact of acute upper respiratory infection, presumed viral (the common cold). WURSS-21 was the short version of this validated survey. The QoL domain of WURSS-21 consisted of 9 questions. Participants rated each QoL questions indicating how cold interfered with their ability to perform daily activities, and the responses were evaluated on a scale ranging from 0 to 7, where 0=Not at all and 7=Severely. Thus, the minimum and maximum possible total scores were 0 and 7 respectively, where higher scores indicated more negative impact on QoL. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.
Outcome measures
| Measure |
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
|---|---|---|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Work Outside the Home
Day 1
|
-0.35 score on a scale
Standard Deviation 2.22
|
-0.32 score on a scale
Standard Deviation 1.84
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Work Outside the Home
Day 2
|
-1.25 score on a scale
Standard Deviation 2.04
|
-0.78 score on a scale
Standard Deviation 2.08
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Work Outside the Home
Day 3
|
-2.01 score on a scale
Standard Deviation 2.05
|
-1.46 score on a scale
Standard Deviation 2.00
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Work Outside the Home
Day 4
|
-2.06 score on a scale
Standard Deviation 2.53
|
-1.71 score on a scale
Standard Deviation 2.09
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Work Outside the Home
Day 5
|
-2.10 score on a scale
Standard Deviation 2.21
|
-2.11 score on a scale
Standard Deviation 2.07
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Work Outside the Home
Day 6
|
-2.26 score on a scale
Standard Deviation 1.96
|
-2.47 score on a scale
Standard Deviation 2.07
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Work Outside the Home
Day 7
|
-2.33 score on a scale
Standard Deviation 2.73
|
-2.40 score on a scale
Standard Deviation 2.06
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Work Outside the Home
EOT
|
-2.64 score on a scale
Standard Deviation 2.38
|
-2.51 score on a scale
Standard Deviation 2.28
|
PRIMARY outcome
Timeframe: Baseline and up to Day 7 or EOTPopulation: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).
The WURSS was an evaluative illness specific quality of life instrument, designed to assess the negative impact of acute upper respiratory infection, presumed viral (the common cold). WURSS-21 was the short version of this validated survey. The QoL domain of WURSS-21 consisted of 9 questions. Participants rated each QoL questions indicating how cold interfered with their ability to perform daily activities, and the responses were evaluated on a scale ranging from 0 to 7, where 0=Not at all and 7=Severely. Thus, the minimum and maximum possible total scores were 0 and 7 respectively, where higher scores indicated more negative impact on QoL. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.
Outcome measures
| Measure |
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
|---|---|---|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Work Inside the Home
Day 1
|
-0.29 score on a scale
Standard Deviation 1.72
|
-0.27 score on a scale
Standard Deviation 1.77
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Work Inside the Home
Day 2
|
-1.21 score on a scale
Standard Deviation 1.80
|
-0.88 score on a scale
Standard Deviation 1.88
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Work Inside the Home
Day 3
|
-1.98 score on a scale
Standard Deviation 1.90
|
-1.40 score on a scale
Standard Deviation 2.00
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Work Inside the Home
Day 4
|
-2.01 score on a scale
Standard Deviation 2.34
|
-1.86 score on a scale
Standard Deviation 1.91
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Work Inside the Home
Day 5
|
-2.10 score on a scale
Standard Deviation 2.14
|
-2.21 score on a scale
Standard Deviation 1.93
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Work Inside the Home
Day 6
|
-2.21 score on a scale
Standard Deviation 1.87
|
-2.78 score on a scale
Standard Deviation 1.92
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Work Inside the Home
Day 7
|
-2.29 score on a scale
Standard Deviation 2.19
|
-2.40 score on a scale
Standard Deviation 1.76
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Work Inside the Home
EOT
|
-2.65 score on a scale
Standard Deviation 2.07
|
-2.41 score on a scale
Standard Deviation 2.10
|
PRIMARY outcome
Timeframe: Baseline and up to Day 7 or EOTPopulation: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).
The WURSS was an evaluative illness specific quality of life instrument, designed to assess the negative impact of acute upper respiratory infection, presumed viral (the common cold). WURSS-21 was the short version of this validated survey. The QoL domain of WURSS-21 consisted of 9 questions. Participants rated each QoL questions indicating how cold interfered with their ability to perform daily activities, and the responses were evaluated on a scale ranging from 0 to 7, where 0=Not at all and 7=Severely. Thus, the minimum and maximum possible total scores were 0 and 7 respectively, where higher scores indicated more negative impact on QoL. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.
Outcome measures
| Measure |
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
|---|---|---|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Interact With Others
Day 1
|
-0.28 score on a scale
Standard Deviation 2.12
|
-0.45 score on a scale
Standard Deviation 1.97
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Interact With Others
Day 2
|
-1.31 score on a scale
Standard Deviation 2.04
|
-1.12 score on a scale
Standard Deviation 2.07
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Interact With Others
Day 3
|
-2.16 score on a scale
Standard Deviation 2.07
|
-1.82 score on a scale
Standard Deviation 2.11
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Interact With Others
Day 4
|
-2.20 score on a scale
Standard Deviation 2.30
|
-2.01 score on a scale
Standard Deviation 2.10
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Interact With Others
Day 5
|
-2.40 score on a scale
Standard Deviation 2.14
|
-2.43 score on a scale
Standard Deviation 1.85
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Interact With Others
Day 6
|
-2.36 score on a scale
Standard Deviation 1.98
|
-3.07 score on a scale
Standard Deviation 1.98
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Interact With Others
Day 7
|
-2.52 score on a scale
Standard Deviation 1.97
|
-3.07 score on a scale
Standard Deviation 1.67
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Interact With Others
EOT
|
-2.88 score on a scale
Standard Deviation 2.15
|
-2.77 score on a scale
Standard Deviation 2.21
|
PRIMARY outcome
Timeframe: Baseline and up to Day 7 or EOTPopulation: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).
The WURSS was an evaluative illness specific quality of life instrument, designed to assess the negative impact of acute upper respiratory infection, presumed viral (the common cold). WURSS-21 was the short version of this validated survey. The QoL domain of WURSS-21 consisted of 9 questions. Participants rated each QoL questions indicating how cold interfered with their ability to perform daily activities, and the responses were evaluated on a scale ranging from 0 to 7, where 0=Not at all and 7=Severely. Thus, the minimum and maximum possible total scores were 0 and 7 respectively, where higher scores indicated more negative impact on QoL. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.
Outcome measures
| Measure |
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
|---|---|---|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Live Your Personal Life
Day 1
|
-0.15 score on a scale
Standard Deviation 2.11
|
-0.55 score on a scale
Standard Deviation 1.82
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Live Your Personal Life
Day 2
|
-1.42 score on a scale
Standard Deviation 1.95
|
-1.05 score on a scale
Standard Deviation 2.07
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Live Your Personal Life
Day 3
|
-2.30 score on a scale
Standard Deviation 2.02
|
-1.89 score on a scale
Standard Deviation 2.08
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Live Your Personal Life
Day 4
|
-2.29 score on a scale
Standard Deviation 2.19
|
-1.94 score on a scale
Standard Deviation 2.09
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Live Your Personal Life
Day 5
|
-2.29 score on a scale
Standard Deviation 1.95
|
-2.61 score on a scale
Standard Deviation 2.15
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Live Your Personal Life
Day 6
|
-2.46 score on a scale
Standard Deviation 1.92
|
-3.09 score on a scale
Standard Deviation 2.00
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Live Your Personal Life
Day 7
|
-2.38 score on a scale
Standard Deviation 1.75
|
-2.73 score on a scale
Standard Deviation 2.09
|
|
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Live Your Personal Life
EOT
|
-2.93 score on a scale
Standard Deviation 2.07
|
-2.76 score on a scale
Standard Deviation 2.30
|
SECONDARY outcome
Timeframe: Baseline and up to Day 7 or EOTPopulation: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).
QoL factors were assessed using specific questions related to social activities, feeling self-conscious around people, coughing in public, falling asleep, sleeping through the night, energy, and motivation. Participants rated their response to questions on a scale ranging from 0 to 7, where 0= Not at all and 7= Severely. Thus, the minimum and maximum score for each question was 0 and 7 respectively, where higher scores indicated more negative impact on QoL. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.
Outcome measures
| Measure |
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
|---|---|---|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Social Activities
Day 1
|
-2.51 score on a scale
Standard Deviation 2.15
|
-2.70 score on a scale
Standard Deviation 1.95
|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Social Activities
Day 2
|
-3.15 score on a scale
Standard Deviation 2.13
|
-2.97 score on a scale
Standard Deviation 2.04
|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Social Activities
Day 3
|
-3.58 score on a scale
Standard Deviation 1.88
|
-3.49 score on a scale
Standard Deviation 2.01
|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Social Activities
Day 4
|
-3.99 score on a scale
Standard Deviation 1.94
|
-3.79 score on a scale
Standard Deviation 1.85
|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Social Activities
Day 5
|
-3.84 score on a scale
Standard Deviation 2.12
|
-4.00 score on a scale
Standard Deviation 1.81
|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Social Activities
Day 6
|
-4.11 score on a scale
Standard Deviation 1.97
|
-4.40 score on a scale
Standard Deviation 1.86
|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Social Activities
Day 7
|
-3.57 score on a scale
Standard Deviation 1.99
|
-4.86 score on a scale
Standard Deviation 2.41
|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Social Activities
EOT
|
-4.29 score on a scale
Standard Deviation 1.90
|
-4.34 score on a scale
Standard Deviation 2.07
|
SECONDARY outcome
Timeframe: Baseline and up to Day 7 or EOTPopulation: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).
QoL factors were assessed using specific questions related to social activities, feeling self-conscious around people, coughing in public, falling asleep, sleeping through the night, energy, and motivation. Participants rated their response to questions on a scale ranging from 0 to 7, where 0= Not at all and 7= Severely. Thus, the minimum and maximum score for each question was 0 and 7 respectively, where higher scores indicated more negative impact on QoL. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.
Outcome measures
| Measure |
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
|---|---|---|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Self-conscious Around People
Day 2
|
-2.65 score on a scale
Standard Deviation 2.10
|
-2.78 score on a scale
Standard Deviation 1.85
|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Self-conscious Around People
Day 1
|
-1.91 score on a scale
Standard Deviation 1.93
|
-2.03 score on a scale
Standard Deviation 1.94
|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Self-conscious Around People
Day 3
|
-3.19 score on a scale
Standard Deviation 1.87
|
-3.37 score on a scale
Standard Deviation 2.11
|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Self-conscious Around People
Day 4
|
-3.55 score on a scale
Standard Deviation 2.14
|
-3.55 score on a scale
Standard Deviation 2.22
|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Self-conscious Around People
Day 5
|
-3.53 score on a scale
Standard Deviation 2.09
|
-3.68 score on a scale
Standard Deviation 1.93
|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Self-conscious Around People
Day 6
|
-3.55 score on a scale
Standard Deviation 2.13
|
-4.31 score on a scale
Standard Deviation 1.83
|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Self-conscious Around People
Day 7
|
-3.48 score on a scale
Standard Deviation 2.48
|
-4.64 score on a scale
Standard Deviation 1.45
|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Self-conscious Around People
EOT
|
-3.97 score on a scale
Standard Deviation 1.86
|
-4.21 score on a scale
Standard Deviation 2.01
|
SECONDARY outcome
Timeframe: Baseline and up to Day 7 or EOTPopulation: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).
QoL factors were assessed using specific questions related to social activities, feeling self-conscious around people, coughing in public, falling asleep, sleeping through the night, energy, and motivation. Participants rated their response to questions on a scale ranging from 0 to 7, where 0= Not at all and 7= Severely. Thus, the minimum and maximum score for each question was 0 and 7 respectively, where higher scores indicated more negative impact on QoL. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.
Outcome measures
| Measure |
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
|---|---|---|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Coughing in Public
Day 1
|
-2.03 score on a scale
Standard Deviation 2.09
|
-2.23 score on a scale
Standard Deviation 1.76
|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Coughing in Public
Day 2
|
-2.93 score on a scale
Standard Deviation 2.09
|
-2.96 score on a scale
Standard Deviation 2.08
|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Coughing in Public
Day 3
|
-3.44 score on a scale
Standard Deviation 1.98
|
-3.63 score on a scale
Standard Deviation 2.21
|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Coughing in Public
Day 4
|
-3.83 score on a scale
Standard Deviation 2.20
|
-3.73 score on a scale
Standard Deviation 2.19
|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Coughing in Public
Day 5
|
-3.86 score on a scale
Standard Deviation 2.17
|
-4.09 score on a scale
Standard Deviation 1.95
|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Coughing in Public
Day 6
|
-3.89 score on a scale
Standard Deviation 2.20
|
-4.48 score on a scale
Standard Deviation 2.09
|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Coughing in Public
Day 7
|
-3.57 score on a scale
Standard Deviation 2.23
|
-4.93 score on a scale
Standard Deviation 2.20
|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Coughing in Public
EOT
|
-4.29 score on a scale
Standard Deviation 2.18
|
-4.64 score on a scale
Standard Deviation 1.93
|
SECONDARY outcome
Timeframe: Baseline and up to Day 7 or EOTPopulation: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).
QoL factors were assessed using specific questions related to social activities, feeling self-conscious around people, coughing in public, falling asleep, sleeping through the night, energy, and motivation. Participants rated their response to questions on a scale ranging from 0 to 7, where 0= Not at all and 7= Severely. Thus, the minimum and maximum score for each question was 0 and 7 respectively, where higher scores indicated more negative impact on QoL. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.
Outcome measures
| Measure |
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
|---|---|---|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Falling Asleep
Day 1
|
-2.86 score on a scale
Standard Deviation 1.88
|
-3.40 score on a scale
Standard Deviation 2.08
|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Falling Asleep
Day 2
|
-3.35 score on a scale
Standard Deviation 1.93
|
-3.54 score on a scale
Standard Deviation 1.91
|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Falling Asleep
Day 3
|
-4.19 score on a scale
Standard Deviation 1.75
|
-4.27 score on a scale
Standard Deviation 1.91
|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Falling Asleep
Day 4
|
-4.35 score on a scale
Standard Deviation 1.99
|
-4.39 score on a scale
Standard Deviation 1.89
|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Falling Asleep
Day 5
|
-4.02 score on a scale
Standard Deviation 2.19
|
-4.43 score on a scale
Standard Deviation 1.58
|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Falling Asleep
Day 6
|
-4.26 score on a scale
Standard Deviation 2.11
|
-4.90 score on a scale
Standard Deviation 1.82
|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Falling Asleep
Day 7
|
-4.33 score on a scale
Standard Deviation 1.80
|
-5.21 score on a scale
Standard Deviation 1.93
|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Falling Asleep
EOT
|
-4.86 score on a scale
Standard Deviation 1.66
|
-5.07 score on a scale
Standard Deviation 1.66
|
SECONDARY outcome
Timeframe: Baseline and up to Day 7 or EOTPopulation: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).
QoL factors were assessed using specific questions related to social activities, feeling self-conscious around people, coughing in public, falling asleep, sleeping through the night, energy, and motivation. Participants rated their response to questions on a scale ranging from 0 to 7, where 0= Not at all and 7= Severely. Thus, the minimum and maximum score for each question was 0 and 7 respectively, where higher scores indicated more negative impact on QoL. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.
Outcome measures
| Measure |
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
|---|---|---|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Sleeping Through the Night
Day 1
|
-3.05 score on a scale
Standard Deviation 1.95
|
-3.51 score on a scale
Standard Deviation 2.06
|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Sleeping Through the Night
Day 2
|
-3.40 score on a scale
Standard Deviation 1.92
|
-3.73 score on a scale
Standard Deviation 2.03
|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Sleeping Through the Night
Day 3
|
-4.08 score on a scale
Standard Deviation 1.86
|
-4.28 score on a scale
Standard Deviation 1.93
|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Sleeping Through the Night
Day 4
|
-4.16 score on a scale
Standard Deviation 2.06
|
-4.40 score on a scale
Standard Deviation 1.92
|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Sleeping Through the Night
Day 5
|
-3.92 score on a scale
Standard Deviation 2.09
|
-4.47 score on a scale
Standard Deviation 1.60
|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Sleeping Through the Night
Day 6
|
-4.11 score on a scale
Standard Deviation 2.04
|
-4.88 score on a scale
Standard Deviation 1.58
|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Sleeping Through the Night
Day 7
|
-4.19 score on a scale
Standard Deviation 1.83
|
-5.00 score on a scale
Standard Deviation 1.66
|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Sleeping Through the Night
EOT
|
-4.91 score on a scale
Standard Deviation 1.64
|
-5.12 score on a scale
Standard Deviation 1.55
|
SECONDARY outcome
Timeframe: Baseline and up to Day 7 or EOTPopulation: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).
QoL factors were assessed using specific questions related to social activities, feeling self-conscious around people, coughing in public, falling asleep, sleeping through the night, energy, and motivation. Participants rated their response to questions on a scale ranging from 0 to 7, where 0= Not at all and 7= Severely. Thus, the minimum and maximum score for each question was 0 and 7 respectively, where higher scores indicated more negative impact on QoL. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.
Outcome measures
| Measure |
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
|---|---|---|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Energy
Day 1
|
-2.33 score on a scale
Standard Deviation 2.21
|
-2.39 score on a scale
Standard Deviation 1.95
|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Energy
Day 2
|
-3.17 score on a scale
Standard Deviation 2.12
|
-2.75 score on a scale
Standard Deviation 2.00
|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Energy
Day 3
|
-3.70 score on a scale
Standard Deviation 1.94
|
-3.42 score on a scale
Standard Deviation 1.89
|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Energy
Day 4
|
-4.14 score on a scale
Standard Deviation 2.05
|
-3.79 score on a scale
Standard Deviation 1.89
|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Energy
Day 5
|
-3.84 score on a scale
Standard Deviation 1.90
|
-3.83 score on a scale
Standard Deviation 1.41
|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Energy
Day 6
|
-4.11 score on a scale
Standard Deviation 1.96
|
-4.21 score on a scale
Standard Deviation 1.69
|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Energy
Day 7
|
-3.81 score on a scale
Standard Deviation 1.86
|
-4.36 score on a scale
Standard Deviation 1.82
|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Energy
EOT
|
-4.53 score on a scale
Standard Deviation 1.73
|
-4.38 score on a scale
Standard Deviation 1.71
|
SECONDARY outcome
Timeframe: Baseline and up to Day 7 or EOTPopulation: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).
QoL factors were assessed using specific questions related to social activities, feeling self-conscious around people, coughing in public, falling asleep, sleeping through the night, energy, and motivation. Participants rated their response to questions on a scale ranging from 0 to 7, where 0= Not at all and 7= Severely. Thus, the minimum and maximum score for each question was 0 and 7 respectively, where higher scores indicated more negative impact on QoL. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.
Outcome measures
| Measure |
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
|---|---|---|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Motivation
Day 1
|
-2.21 score on a scale
Standard Deviation 2.12
|
-2.34 score on a scale
Standard Deviation 1.94
|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Motivation
Day 2
|
-2.97 score on a scale
Standard Deviation 2.14
|
-2.52 score on a scale
Standard Deviation 1.94
|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Motivation
Day 3
|
-3.50 score on a scale
Standard Deviation 2.10
|
-3.41 score on a scale
Standard Deviation 1.77
|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Motivation
Day 4
|
-3.93 score on a scale
Standard Deviation 2.12
|
-3.67 score on a scale
Standard Deviation 1.83
|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Motivation
Day 5
|
-3.76 score on a scale
Standard Deviation 1.96
|
-4.02 score on a scale
Standard Deviation 1.35
|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Motivation
Day 6
|
-4.00 score on a scale
Standard Deviation 2.00
|
-4.29 score on a scale
Standard Deviation 1.53
|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Motivation
Day 7
|
-3.86 score on a scale
Standard Deviation 2.06
|
-4.64 score on a scale
Standard Deviation 1.39
|
|
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Motivation
EOT
|
-4.37 score on a scale
Standard Deviation 1.79
|
-4.27 score on a scale
Standard Deviation 1.77
|
SECONDARY outcome
Timeframe: Baseline and up to Day 7 or EOTPopulation: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).
The QoL factors were categorized into 4 categories - Sleep quality, Vitality, Physical activity and Social activity. Sleep quality category included 3 individual questions - Sleep well (WURSS-21: Question 13), Falling asleep (QoL: Question 4) and Sleep through the night (QoL: Question 5). Participants rated each question, and the responses were evaluated on a scale ranging from 0 to 7, where 0=Not at all and 7=Severely. The individual question score was added to derive categorized QoL score. Thus, the minimum and maximum possible total scores was 0 and 21 respectively, where higher scores indicated more negative impact on QoL. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.
Outcome measures
| Measure |
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
|---|---|---|
|
Mean Change From Baseline in Categorized QoL Questions Score: Sleep Quality
Day 1
|
-6.85 score on a scale
Standard Deviation 4.60
|
-7.72 score on a scale
Standard Deviation 4.93
|
|
Mean Change From Baseline in Categorized QoL Questions Score: Sleep Quality
Day 2
|
-8.65 score on a scale
Standard Deviation 5.38
|
-8.87 score on a scale
Standard Deviation 4.99
|
|
Mean Change From Baseline in Categorized QoL Questions Score: Sleep Quality
Day 3
|
-10.82 score on a scale
Standard Deviation 4.90
|
-10.90 score on a scale
Standard Deviation 5.03
|
|
Mean Change From Baseline in Categorized QoL Questions Score: Sleep Quality
Day 4
|
-11.25 score on a scale
Standard Deviation 6.15
|
-11.43 score on a scale
Standard Deviation 4.75
|
|
Mean Change From Baseline in Categorized QoL Questions Score: Sleep Quality
Day 5
|
-10.78 score on a scale
Standard Deviation 6.25
|
-11.98 score on a scale
Standard Deviation 4.07
|
|
Mean Change From Baseline in Categorized QoL Questions Score: Sleep Quality
Day 6
|
-11.47 score on a scale
Standard Deviation 6.09
|
-13.17 score on a scale
Standard Deviation 4.62
|
|
Mean Change From Baseline in Categorized QoL Questions Score: Sleep Quality
Day 7
|
-10.76 score on a scale
Standard Deviation 4.91
|
-14.00 score on a scale
Standard Deviation 5.32
|
|
Mean Change From Baseline in Categorized QoL Questions Score: Sleep Quality
EOT
|
-13.40 score on a scale
Standard Deviation 4.89
|
-13.43 score on a scale
Standard Deviation 4.82
|
SECONDARY outcome
Timeframe: Baseline and up to Day 7 or EOTPopulation: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).
The QoL factors were categorized into 4 categories - Sleep quality, Vitality, Physical activity and Social activity. Vitality category was assessed using 3 individual questions - Energy (QoL: Question 6), Motivation (QoL: Question 7), and Feel tired (WURSS-21: Question 11). Participants rated each question, and the responses were evaluated on a scale ranging from 0 to 7, where 0=Not at all and 7=Severely. The individual question score was added to derive categorized QoL score. Thus, the minimum and maximum possible total score was 0 and 21 respectively, where higher scores indicated more negative impact on QoL. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.
Outcome measures
| Measure |
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
|---|---|---|
|
Mean Change From Baseline in Categorized QoL Questions Score: Vitality
Day 1
|
-5.12 score on a scale
Standard Deviation 5.00
|
-5.36 score on a scale
Standard Deviation 4.22
|
|
Mean Change From Baseline in Categorized QoL Questions Score: Vitality
Day 2
|
-7.76 score on a scale
Standard Deviation 5.21
|
-6.74 score on a scale
Standard Deviation 4.49
|
|
Mean Change From Baseline in Categorized QoL Questions Score: Vitality
Day 3
|
-9.88 score on a scale
Standard Deviation 5.07
|
-9.04 score on a scale
Standard Deviation 4.53
|
|
Mean Change From Baseline in Categorized QoL Questions Score: Vitality
Day 4
|
-11.00 score on a scale
Standard Deviation 5.80
|
-10.12 score on a scale
Standard Deviation 4.84
|
|
Mean Change From Baseline in Categorized QoL Questions Score: Vitality
Day 5
|
-10.43 score on a scale
Standard Deviation 5.31
|
-10.75 score on a scale
Standard Deviation 3.96
|
|
Mean Change From Baseline in Categorized QoL Questions Score: Vitality
Day 6
|
-11.53 score on a scale
Standard Deviation 5.14
|
-11.95 score on a scale
Standard Deviation 4.42
|
|
Mean Change From Baseline in Categorized QoL Questions Score: Vitality
Day 7
|
-10.48 score on a scale
Standard Deviation 5.27
|
-12.36 score on a scale
Standard Deviation 4.36
|
|
Mean Change From Baseline in Categorized QoL Questions Score: Vitality
EOT
|
-12.37 score on a scale
Standard Deviation 4.74
|
-12.15 score on a scale
Standard Deviation 4.45
|
SECONDARY outcome
Timeframe: Baseline and up to Day 7 or EOTPopulation: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).
The QoL factors were categorized into 4 categories - Sleep quality, Vitality, Physical activity and Social activity. Physical Activities were assessed using 3 individual questions - Breathe easily (WURSS-21: Question 14), Walk, climb stairs, exercise (WURSS-21: Question 15) and Accomplish daily activities (WURSS-21: Question 16). Participants rated each question, and the responses were evaluated on a scale ranging from 0 to 7, where 0=Not at all and 7=Severely. The individual question score was added to derive categorized QoL score. Thus, the minimum and maximum possible total score was 0 and 21 respectively, where higher scores indicated more negative impact on QoL. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.
Outcome measures
| Measure |
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
|---|---|---|
|
Mean Change From Baseline in Categorized QoL Questions Score: Physical Activities
Day 1
|
-1.35 score on a scale
Standard Deviation 4.56
|
-0.84 score on a scale
Standard Deviation 4.11
|
|
Mean Change From Baseline in Categorized QoL Questions Score: Physical Activities
Day 2
|
-4.09 score on a scale
Standard Deviation 4.76
|
-2.45 score on a scale
Standard Deviation 5.04
|
|
Mean Change From Baseline in Categorized QoL Questions Score: Physical Activities
Day 3
|
-6.14 score on a scale
Standard Deviation 5.03
|
-4.41 score on a scale
Standard Deviation 4.89
|
|
Mean Change From Baseline in Categorized QoL Questions Score: Physical Activities
Day 4
|
-6.75 score on a scale
Standard Deviation 6.37
|
-5.64 score on a scale
Standard Deviation 5.06
|
|
Mean Change From Baseline in Categorized QoL Questions Score: Physical Activities
Day 5
|
-6.38 score on a scale
Standard Deviation 5.56
|
-6.43 score on a scale
Standard Deviation 4.69
|
|
Mean Change From Baseline in Categorized QoL Questions Score: Physical Activities
Day 6
|
-6.74 score on a scale
Standard Deviation 4.18
|
-8.24 score on a scale
Standard Deviation 4.24
|
|
Mean Change From Baseline in Categorized QoL Questions Score: Physical Activities
Day 7
|
-6.38 score on a scale
Standard Deviation 4.24
|
-7.20 score on a scale
Standard Deviation 4.41
|
|
Mean Change From Baseline in Categorized QoL Questions Score: Physical Activities
EOT
|
-8.39 score on a scale
Standard Deviation 5.37
|
-7.23 score on a scale
Standard Deviation 5.49
|
SECONDARY outcome
Timeframe: Baseline and up to Day 7 or EOTPopulation: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).
The QoL factors were categorized into 4 categories - Sleep quality, Vitality, Physical activity and Social activity. Social Activities were assessed using 4 individual questions - Interact with others (WURSS-21: Question 19), Less comfortable in social activities (QoL: Question 1), Self-conscious around others (QoL: Question 2) and Coughing in public (QoL: Question 3). Participants rated each question and the responses were evaluated on a scale ranging from 0 to 7, where 0=Not at all and 7=Severely. The individual question score was added to derive categorized QoL score. Thus, the minimum and maximum possible total score was 0 and 28 respectively, where higher scores indicated more negative impact on QoL. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.
Outcome measures
| Measure |
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
|---|---|---|
|
Mean Change From Baseline in Categorized QoL Questions Score: Social Activities
Day 1
|
-6.70 score on a scale
Standard Deviation 6.05
|
-7.38 score on a scale
Standard Deviation 5.13
|
|
Mean Change From Baseline in Categorized QoL Questions Score: Social Activities
Day 2
|
-9.99 score on a scale
Standard Deviation 6.77
|
-9.90 score on a scale
Standard Deviation 6.19
|
|
Mean Change From Baseline in Categorized QoL Questions Score: Social Activities
Day 3
|
-12.36 score on a scale
Standard Deviation 6.48
|
-12.34 score on a scale
Standard Deviation 6.80
|
|
Mean Change From Baseline in Categorized QoL Questions Score: Social Activities
Day 4
|
-13.57 score on a scale
Standard Deviation 7.43
|
-13.12 score on a scale
Standard Deviation 6.90
|
|
Mean Change From Baseline in Categorized QoL Questions Score: Social Activities
Day 5
|
-13.61 score on a scale
Standard Deviation 7.50
|
-14.13 score on a scale
Standard Deviation 6.40
|
|
Mean Change From Baseline in Categorized QoL Questions Score: Social Activities
Day 6
|
-13.87 score on a scale
Standard Deviation 7.14
|
-16.21 score on a scale
Standard Deviation 6.84
|
|
Mean Change From Baseline in Categorized QoL Questions Score: Social Activities
Day 7
|
-13.14 score on a scale
Standard Deviation 7.86
|
-17.50 score on a scale
Standard Deviation 7.10
|
|
Mean Change From Baseline in Categorized QoL Questions Score: Social Activities
EOT
|
-15.43 score on a scale
Standard Deviation 6.67
|
-15.93 score on a scale
Standard Deviation 6.88
|
Adverse Events
Robitussin Cough Syrup (Daytime)
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
Robitussin Cough Syrup (Daytime)
n=115 participants at risk
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=112 participants at risk
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
|
|---|---|---|
|
Gastrointestinal disorders
Diarrhoea
|
0.87%
1/115 • Immediately after a participant was randomized within the trial and until 2 days following the last administration of study product (approximately up to 10 days).
An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study product including an acclimatization product (or medical device). A serious AE (SAE) was a particular category of AE where the adverse outcome was serious.
|
0.00%
0/112 • Immediately after a participant was randomized within the trial and until 2 days following the last administration of study product (approximately up to 10 days).
An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study product including an acclimatization product (or medical device). A serious AE (SAE) was a particular category of AE where the adverse outcome was serious.
|
|
Gastrointestinal disorders
Nausea
|
0.87%
1/115 • Immediately after a participant was randomized within the trial and until 2 days following the last administration of study product (approximately up to 10 days).
An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study product including an acclimatization product (or medical device). A serious AE (SAE) was a particular category of AE where the adverse outcome was serious.
|
0.00%
0/112 • Immediately after a participant was randomized within the trial and until 2 days following the last administration of study product (approximately up to 10 days).
An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study product including an acclimatization product (or medical device). A serious AE (SAE) was a particular category of AE where the adverse outcome was serious.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee HALEON agreements may vary with individual investigators but will not prohibit any investigator from publishing. HALEON supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.
- Publication restrictions are in place
Restriction type: OTHER